NCT05578092
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05578092
Title A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Mirati Therapeutics Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Local Institution - 001-108 New Haven Connecticut 06520 United States Details
Local Institution - 001-119 Newark Delaware 19713-2055 United States Details
Local Institution - 001-111 Orlando Florida 32827-7400 United States Details
Local Institution - 001-103 Baltimore Maryland 21287 United States Details
Local Institution - 001-110 Rochester Minnesota 55905-0001 United States Details
Local Institution - 001-115 Hackensack New Jersey 07601-2191 United States Details
Local Institution - 001-106 Cincinnati Ohio 45219-2364 United States Details
Local Institution - 001-109 Portland Oregon 97239-3011 United States Details
Local Institution - 001-116 Pittsburgh Pennsylvania 15232 United States Details
Local Institution - 001-101 Nashville Tennessee 37203 United States Details
Local Institution - 001-102 Nashville Tennessee 37203 United States Details
Local Institution - 001-112 Dallas Texas 75246-2003 United States Details
Local Institution - 001-122 Fort Worth Texas 76104-2154 United States Details
Local Institution - 001-107 Houston Texas 77030 United States Details
Local Institution - 001-123 Tyler Texas 75708-3154 United States Details
Local Institution - 001-104 Fairfax Virginia 22031 United States Details
Local Institution - 001-105 Seattle Washington 98109 United States Details
Local Institution - 001-114 Rio Piedras 00935 Puerto Rico Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field